CytoDyn, Inc. (CYDY)
| Market Cap | 1.09B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.39M |
| Shares Out | 612.88M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | 10.81 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 15 |
| Last Price | $1.78 |
| Previous Close | $1.84 |
| Change ($) | -0.07 |
| Change (%) | -3.53% |
| Day's Open | 1.82 |
| Day's Range | 1.76 - 1.83 |
| Day's Volume | 1,024,543 |
| 52-Week Range | 1.63 - 10.01 |
SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible false ...
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
CytoDyn Inc (OTCQB:CYDY) announced that the scientific journal Nature Communications published a study showing that leronlimab prevented nonhuman primates from being infected with Simian Human Immunodef...
Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial
Finding trending penny stocks in 2021 can be difficult; here's 4 to help you on your search The post Trending Penny Stocks to Buy Right Now? 4 For Your Watchlist appeared first on Penny Stocks to Buy, P...
CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, revealed that Chiral Pharma Corporation placed its first purchase order for leronlimab under a comp...
VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagoni...
Chiral is simultaneously working on application for Emergency Use Authorization
12:27pm: Nasdaq joins the other indices in the green In the US, the Dow was up 148 points, 0.4%, to 34,471 at midday. The Nasdaq added 31 points, 0.2%, to 13,769, and the S&P 500 improved 14 points, 0.3...
Investors in a biotech startup developing a COVID-19 treatment claim the firm's leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronaviru...
CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, has said that its Brazilian distribution partner Biomm SA (BVMF:BIOM3) plans to submit an authoriza...
VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...
CytoDyn Inc (OTCQB:CYDY) has found its new CFO in-house, promoting Vice President, Corporate Controller, Antonio Migliarese, the company announced. Migliarese joined CytoDyn in January 2020, and he has...
VANCOUVER, Washington, May 20, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...
After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to re...
CytoDyn Inc (OTCQB:CYDY) plans to submit the topline results of its CD12 Phase 3 clinical trial of Vyrologix (leronlimab-PRO 140) for severe to critically ill COVID-19 patients to regulatory agencies, i...
The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is effective. In March, the Phase 3 trial of Cy...
Finalized data analysis shows CD12 trial reached almost all of its major secondary endpoints in a subpopulation (62 patients) of critically ill COVID-19
VANCOUVER, Washington, May 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...
Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...
New York, New York--(Newsfile Corp. - May 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...
New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytoD...
New York, New York--(Newsfile Corp. - May 15, 2021) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 and...
New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytoDyn Inc. (OTCQB: CYDY) alleging that the ...
New York, New York--(Newsfile Corp. - May 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...
New York, New York--(Newsfile Corp. - May 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased CytoDyn Inc. ("CytoDy...
Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...
New Orleans, Louisiana--(Newsfile Corp. - May 13, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have unti...
LOS ANGELES--(BUSINESS WIRE)---- $CYDY #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)
Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...
CytoDyn strikes supply and distribution deal with Indian firm for leronlimb as coronavirus treatment
CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140) for multiple therapeutic indications, has executed an exclusive supply and distribution agreemen...
Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries
NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCMKTS: CYDY). Such investors are advised to contact Ro...
New York, New York--(Newsfile Corp. - May 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTCQB: CYDY) between March 27, 2020 an...
RADNOR, Pa.--(BUSINESS WIRE)---- $CYDY #classaction--Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against CytoDyn Inc. (CYDY)
Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CytoDyn Inc. ("CytoDyn"...
Radnor, Pennsylvania--(Newsfile Corp. - May 11, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States Dist...
Radnor, Pennsylvania--(Newsfile Corp. - May 10, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn") that a securities fraud class actio...
Radnor, Pennsylvania--(Newsfile Corp. - May 7, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn") that a securities fraud class action...
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9
New Orleans, Louisiana--(Newsfile Corp. - May 6, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until...
NEW YORK, May 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March 9, 2021, i...
CytoDyn Inc (OTCQB:CYDY) announced that it has struck an agreement to partner with the Academic Research Organization (ARO) - Albert Einstein Israelite Hospital (AEIH), in São Paulo, Brazil to run two t...
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients
New York, New York--(Newsfile Corp. - May 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytoDyn Inc. (OTCQB: CYDY) alleging that the C...
Radnor, Pennsylvania--(Newsfile Corp. - May 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States Distr...
New York, New York--(Newsfile Corp. - May 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CytoDy...
RADNOR, Pa., May 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuit has been filed against CytoDyn Inc. (OTCMKTS: CYD...
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 a...
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5...
About CYDY
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapi... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol CYDY |